Slingshot members are tracking this event:

Phase 3 MONARCH 2 Data Evaluating Abemaciclib in Patients with Relapsed/Refractory HR+/HER2- Breast Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The two phase 3 trials are combination studies with abemaciclib for the treatment of women with breast cancer.  The Monarch 2 and Monarch 3 study data is expected in Q2 and Q3 of 2017 respectively.  
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Monarch 2 Study, Monarch 3 Study, Breast Cancer, Abemaciclib